U.K. researchers have identified chemical compounds, called tool molecules, that they say are capable of halting active cancer cells, particularly in basal-like breast cancer (BLBC). These tool molecules induce a pro-senescence state in the cancer cells, akin to a dormant phase where they cease dividing and promoting tumor growth.
By forcing the cancer cells into this pro-senescence state, they become vulnerable to senolytic drugs, which can effectively eliminate them. This approach not only targets the cancer cells directly but also potentially enhances their visibility to the immune system, opening up new therapeutic avenues.
Led by Cleo Bishop from Queen Mary University of London, the research team uncovered a pathway to induce pro-senescence in BLBC cells and collaborated with Dundee’s Drug Discovery Unit to develop tool molecules for this purpose.
The innovative 'two-punch' strategy offers a promising alternative to traditional treatments like surgery and chemotherapy for BLBC. These pro-senescence therapies not only halt tumor growth but also stimulate anti-tumor immune responses, presenting novel treatment possibilities. The tool molecules identified through high-content imaging at DDU are now being further evaluated by pharmaceutical company ValiRx. This strategic alliance aims to advance these tool molecules into clinical evaluation.